The following represents disclosure information provided by authors of this abstract. The Gastrointestinal Cancers Symposium Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Cetuximab in combination with irinotecan as second-line treatment in patients with platinum-resistant gastroesophageal cancer (GEC).
Katrine Rahbek Schoennemann
No relevant relationships to disclose
Mette K. N. Yilmaz
No relevant relationships to disclose
Jon Kroll Bjerregaard
No relevant relationships to disclose
Helle Anita Jensen
No relevant relationships to disclose
Kirsten Marie Nielsen
No relevant relationships to disclose
Lene Weber Vestermark
No relevant relationships to disclose
Per Pfeiffer
Consultant or Advisory Role - Merck Serono (U)
Research Funding - Merck Serono